SCHEMBL24735334

SCHEMBL24735334

COc1ccc(C(=O)N2CCN(CCCCC(=O)O)CC2)cc1N1CCC(=O)NC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
DRD2 P14416 4/20 0.47
HTR2A P28223 1/20 0.47
NR3C1 P04150 1/20 0.44
PGR P06401 1/20 0.44
SLC6A4 P31645 1/20 0.44
KCNH2 Q12809 1/20 0.44
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 1/20 0.42
DRD3 P35462 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29841519 1.00 KMT2A (0.48) KMT2AMEN1DRD2HTR2ANR3C1
SCHEMBL24735190 0.99 KMT2A (0.48) KMT2AMEN1DRD2HTR2ANR3C1
SCHEMBL29841476 0.99 KMT2A (0.48) KMT2AMEN1DRD2HTR2ANR3C1
SCHEMBL24735333 0.89 CRBN (0.45) KMT2AMEN1DRD2HTR2ANR3C1
SCHEMBL29841396 0.88 CRBN (0.44) KMT2AMEN1DRD2HTR2ANR3C1
SCHEMBL24735189 0.88 CRBN (0.44) KMT2AMEN1DRD2HTR2ANR3C1
SCHEMBL31255253 0.88 NR3C1 (0.48) KMT2AMEN1DRD2HTR2ANR3C1
SCHEMBL30874154 0.88 TLR9 (0.51) KMT2AMEN1DRD2HTR2ANR3C1
SCHEMBL21409218 0.88 TLR9 (0.51) KMT2AMEN1DRD2HTR2ANR3C1
SCHEMBL31586256 0.86 NR3C1 (0.40) NR3C1PGRSLC6A4KCNH2PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132502-A1 SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed
CN-117042769-A Substituted pyrrolopyrimidines and pyrazolopyrimidines as Bruton's Tyrosine Kinase (BTK) degrading agents 冰洲石生物科技公司 2023-11-10 CN disclosed
US-11530222-B2 Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders ACCUTAR BIOTECHNOLOGY INC. (US) 2022-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530222-B2 Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders BTK, LYN, SYK KMT2A 2358/4885MEN1 4568/4885DRD2 4734/4885
US-20240132502-A1 SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS BTK, LYN, SYK KMT2A 2026/4885MEN1 4466/4885DRD2 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.